| Molecular basis of resistance to azole antifungals A Lupetti, R Danesi, M Campa, M Del Tacca, S Kelly Trends in molecular medicine 8 (2), 76-81, 2002 | 592 | 2002 |
| MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity E Giovannetti, N Funel, GJ Peters, M Del Chiaro, LA Erozenci, E Vasile, ... Cancer research 70 (11), 4528-4538, 2010 | 532 | 2010 |
| Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine E Giovannetti, M Del Tacca, V Mey, N Funel, S Nannizzi, S Ricci, ... Cancer research 66 (7), 3928-3935, 2006 | 436 | 2006 |
| Rechallenge for patients with RAS and BRAF wild-type metastatic colorectal cancer with acquired resistance to first-line cetuximab and irinotecan: a phase 2 single-arm clinical … C Cremolini, D Rossini, E Dell’Aquila, S Lonardi, E Conca, M Del Re, ... JAMA oncology 5 (3), 343-350, 2019 | 380 | 2019 |
| Pharmacogenomics of ABC transporters and its role in cancer chemotherapy A Sparreboom, R Danesi, Y Ando, J Chan, WD Figg Drug Resistance Updates 6 (2), 71-84, 2003 | 316 | 2003 |
| Pharmacokinetic-pharmacodynamic relationships of the anthracycline anticancer drugs R Danesi, S Fogli, A Gennari, P Conte, M Del Tacca Clinical pharmacokinetics 41, 431-444, 2002 | 284 | 2002 |
| The detection of androgen receptor splice variant 7 in plasma-derived exosomal RNA strongly predicts resistance to hormonal therapy in metastatic prostate cancer patients M Del Re, E Biasco, S Crucitta, L Derosa, E Rofi, C Orlandini, M Miccoli, ... European urology 71 (4), 680-687, 2017 | 279 | 2017 |
| Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin–treated advanced non–small cell lung cancer patients C Tibaldi, E Giovannetti, E Vasile, V Mey, AC Laan, S Nannizzi, ... Clinical cancer research 14 (6), 1797-1803, 2008 | 274 | 2008 |
| PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC M Del Re, R Marconcini, G Pasquini, E Rofi, C Vivaldi, F Bloise, ... British journal of cancer 118 (6), 820-824, 2018 | 244 | 2018 |
| Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non–small-cell lung cancer cells E Giovannetti, V Mey, S Nannizzi, G Pasqualetti, L Marini, M Del Tacca, ... Molecular pharmacology 68 (1), 110-118, 2005 | 239 | 2005 |
| Effect of SLCO1B3 Haplotype on Testosterone Transport and Clinical Outcome in Caucasian Patients with Androgen-Independent Prostatic Cancer A Hamada, T Sissung, DK Price, R Danesi, CH Chau, N Sharifi, D Venzon, ... Clinical cancer research 14 (11), 3312-3318, 2008 | 235 | 2008 |
| The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors L Jain, CA Vargo, R Danesi, TM Sissung, DK Price, D Venzon, J Venitz, ... Molecular cancer therapeutics 8 (9), 2496-2508, 2009 | 216 | 2009 |
| The pharmacological bases of the antiangiogenic activity of paclitaxel G Bocci, A Di Paolo, R Danesi Angiogenesis 16, 481-492, 2013 | 211 | 2013 |
| Clinical pharmacology of intravitreal anti-VEGF drugs S Fogli, M Del Re, E Rofi, C Posarelli, M Figus, R Danesi Eye 32 (6), 1010-1020, 2018 | 207 | 2018 |
| Molecular mechanisms underlying the role of microRNAs (miRNAs) in anticancer drug resistance and implications for clinical practice E Giovannetti, A Erozenci, J Smit, R Danesi, GJ Peters Critical reviews in oncology/hematology 81 (2), 103-122, 2012 | 207 | 2012 |
| Pharmacologic disruption of Polycomb Repressive Complex 2 inhibits tumorigenicity and tumor progression in prostate cancer F Crea, EM Hurt, LA Mathews, SM Cabarcas, L Sun, VE Marquez, ... Molecular cancer 10, 1-10, 2011 | 204 | 2011 |
| Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate … E Giovannetti, C Lemos, C Tekle, K Smid, S Nannizzi, JA Rodriguez, ... Molecular pharmacology 73 (4), 1290-1300, 2008 | 201 | 2008 |
| Cardiac toxicity of antineoplastic anthracyclines R Zucchi, R Danesi Current Medicinal Chemistry-Anti-Cancer Agents 3 (2), 151-171, 2003 | 200 | 2003 |
| Management of adverse events associated with tyrosine kinase inhibitors: improving outcomes for patients with hepatocellular carcinoma L Rimassa, R Danesi, T Pressiani, P Merle Cancer Treatment Reviews 77, 20-28, 2019 | 197 | 2019 |
| Biweekly chemotherapy with oxaliplatin, irinotecan, infusional fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer A Falcone, G Masi, G Allegrini, R Danesi, E Pfanner, IM Brunetti, ... Journal of clinical oncology 20 (19), 4006-4014, 2002 | 197 | 2002 |
Marzia Del Re, PharmD, PhDAssociate Prof. of Pharmacology-St. Camillus International University of Medical and Health SciencesVerified email at unicamillus.org
